Is verapamil a double-edged sword in rate control of paroxysmal atrial fibrillation?

Heart Rhythm

Volumn 7, Issue 5, 2010, Pages 584-585

  Raatikainen, M J Pekka ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DRONEDARONE; VERAPAMIL; ANTIARRHYTHMIC AGENT;

BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CATHETER ABLATION; CORONARY SINUS; DRUG EFFICACY; ELECTROGRAPHY; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART RATE; HEART REPOLARIZATION; HUMAN; NOTE; PAROXYSMAL HEART ATRIUM FIBRILLATION; PRIORITY JOURNAL; PULMONARY VEIN; QUALITY OF LIFE; SINUS RHYTHM; SUPERIOR CAVA VEIN; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART ATRIUM; INNERVATION; PATHOLOGY;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIOVENTRICULAR NODE; HEART ATRIA; HEART RATE; HUMANS; PULMONARY VEINS; VERAPAMIL;

EID: 79958245556     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2010.01.033     Document Type: Editorial

References (11)

1. Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009;2:349-361.
2. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-678.
3. Ng J, Kadish AH, Goldberger JJ. Technical considerations for dominant frequency analysis. J Cardiovasc Electrophysiol 2007;18:757-764.
4. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-666.
5. Sanders P, Berenfeld O, Hocini M, et al. Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans. Circulation 2005;112:789-797.
6. Lin YJ, Tai CT, Kao T, et al. Frequency analysis in different types of paroxysmal atrial fibrillation. J Am Coll Cardiol 2006;47:1401-1407.
7. Kushiyama Y, Osaka T, Yokoyama E, et al. Verapamil eliminates the hierarchical nature of activation frequencies from the pulmonary veins to the atria during paroxysmal atrial fibrillation. Heart Rhythm 2010;7:577-583.
8. Duytschaever MF, Garratt CJ, Allessie MA. Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrillation. J Cardiovasc Electrophysiol 2000;11:1375-1385.
9. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary. Eur Heart J 2006;27:1979-2030.
10. Hoy SM, Keam SJ. Dronedarone. Drugs 2009;69:1647-1663.
11. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008;156:527-529.